Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Daniel Watson

Urology Charlotte, NC Medical Doctor

NPI 1689618225 CMS profile 302673

325 Hawthorne Ln Ste 300, Charlotte, NC 28204

Open in the dashboard

General payments

$8,101

298 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Daniel Watson of Charlotte, NC is reported in the CMS Open Payments database as having received $8,101 across 298 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $29 1
2022 General $1,331 51
2021 General $1,740 85
2020 General $3,208 68
2019 General $1,793 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Watson
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Daniel Watson were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Daniel Watson Urology median Middle half National median
2019 $1,793 $480 $147–$1,201 $163
2020 $3,208 $246 $87–$645 $114
2021 $1,740 $358 $111–$1,000 $132
2022 $1,331 $476 $143–$1,263 $149
2023 $0 $560 $168–$1,461 $160
2024 $29 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Bayer HealthCare Pharmaceuticals Inc. $2,110 10 payments
  2. Astellas Pharma US Inc $1,028 50 payments
  3. HealthTronics Mobile Solutions, LLC $850 45 payments
  4. Janssen Biotech, Inc. $688 41 payments
  5. Boston Scientific Corporation $380 18 payments
  6. AbbVie, Inc. $373 21 payments
  7. Dendreon Pharmaceuticals LLC $331 11 payments
  8. Pfizer Inc. $293 16 payments
  9. Aytu BioScience, Inc $228 19 payments
  10. Sun Pharmaceutical Industries Inc. $220 9 payments
  11. Other $1,601 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,961 293 payments
  2. Consulting Fee $1,840 1 payment
  3. Education $300 4 payments
Products named General payments · program years 2019–2024
  1. Nubeqa $1,900 5 payments
  2. XTANDI $857 46 payments
  3. Mobile Cryoblation Services $850 45 payments
  4. ERLEADA $821 42 payments
  5. MYRBETRIQ $463 26 payments
  6. PROVENGE $331 11 payments
  7. LUPRON DEPOT $241 14 payments
  8. Natesto $228 19 payments
  9. Axumin $176 8 payments
  10. ICEFX $171 8 payments
  11. Other $2,522 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

298 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record